Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Jay Olson
Oppenheimer & Co. Inc., Research Division

Welcome to Oppenheimer’s 36th Annual Life Science Conference. I’m Jay Olson, one of the biotech analysts here at Oppenheimer. And it’s a pleasure to welcome you to our discussion with Sagimet Biosciences. And it’s an honor to introduce Dave Happel, the CEO of Sagimet; Rob D’Urso, SVP of New Products; Eduardo, Chief Medical Officer; and Thierry, the Chief Financial Officer. Thanks so much guys for bringing your team here today and making time for us.

David Happel
CEO, President & Director

Thanks, Jay. Thanks for the invitation. Great to be here.

Jay Olson
Oppenheimer & Co. Inc., Research Division

It’s our pleasure, and we’re super excited about Sagimet. You’ve got a lot of interesting things going on. So it’s good timing for the discussion. For those who may not be so familiar with the Sagimet study, Dave, would you like to give us a quick overview?

David Happel
CEO, President & Director

Yes, sure. Thanks, Jay. So Sagimet is a clinical-stage biopharmaceutical company. And our approach really begins with understanding how overexpression or overactivity of fatty acid synthase or FASN plays such a critical role in the development of a number of underserved conditions and our primary focus in MASH, acne in certain solid tumors that are dependent upon FASN for progression of disease. To solve for this overactivity of FASN, we’ve developed a portfolio of FASN inhibitors led by our lead program, denifanstat, they really target an underlying cause that is